Bristol-Myers Gets Key Assets With A Medarex Deal (BMY, MEDX, ABT, JNJ, AMGN, WYE)
Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get a great deal beyond the cancer monoclonal antibody that developed together. The Medarex…